The response to antifibrotic drugs is also heterogeneous among patients, resulting in a lack of FDA-approved antifibrotic drugs for SSc from randomly controlled clinical trials with large number of patients (23–28).Traditional studies identifying anti-fibrotic drugs were conducted in optimized culture microenvironment and these in vitro studies have proposed several anti-fibrotic drugs, including Imatinib mesylate, c-Abl tyrosine kinase, and a line of PPARγ activators (23–28). The gene discussed is PPARG; the disease is systemic sclerosis.